MTOR and mature T-cell and NK-cell non-Hodgkin lymphoma: While monotherapies employing the mTOR inhibitor everolimus or the antimetabolite gemcitabine have shown limited clinical benefit in R/R PTCL, our preclinical investigations demonstrate that their combined administration produces synergistic effects by inhibiting cell proliferation and enhancing apoptosis in everolimus-resistant PTCL cell lines.